Welcome to our dedicated page for Altamira Therapeutics news (Ticker: CYTO), a resource for investors and traders seeking the latest updates and insights on Altamira Therapeutics stock.
Altamira Therapeutics Ltd. (historically Nasdaq: CYTO) generates news primarily around its RNA delivery platforms, legacy therapeutic assets, and capital markets activity. Company announcements describe ongoing development of its peptide-based nanoparticle technologies OligoPhore and SemaPhore for efficient RNA delivery to extrahepatic tissues, along with preclinical progress in its flagship siRNA programs AM-401 for KRAS-driven cancer and AM-411 for rheumatoid arthritis.
News items frequently cover business updates and financial results, where Altamira outlines its strategic repositioning around RNA delivery, reports on research milestones, and discusses collaborations with biotech and pharma partners. Press releases have highlighted independent preclinical publications using its SemaPhore platform in oncology and inflammatory disease models, as well as internal advances in nanoparticle formulation and process development.
Altamira-related news also includes developments from its associated company Altamira Medica AG and the commercial-stage nasal spray Bentrio. Announcements have detailed license and distribution agreements for Bentrio in regions such as East and South East Asia and Scandinavia, expansion of partner territories, and clinical data supporting its use in allergic rhinitis and protection against airborne particles. Additional releases have addressed topics like Bentrio’s suitability for athletes based on analytical testing for substances on the World Anti-Doping Agency list.
Capital markets and listing updates form another important category of news. The company has issued releases on public offerings of common shares and warrants, use of proceeds for working capital and research, and its transition from the Nasdaq Capital Market to the OTCQB marketplace following a Nasdaq delisting decision related to the minimum bid price rule. Investors following CYTO can use this news stream to monitor scientific progress, partnering activity, commercialization steps for Bentrio, and changes in trading venue or financing transactions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Altamira Therapeutics (Nasdaq:CYTO) announced the publication of positive results from its TRAVERS Phase 2 trial assessing AM-125 (intranasal betahistine) for surgery-induced acute vestibular syndrome (AVS). The study, published in Otology & Neurotology, involved 124 patients across Europe and demonstrated good tolerability alongside significant improvements in balance and vestibular dysfunction symptoms. Specifically, patients receiving 20 mg of AM-125 maintained balance for an average of 10.9 seconds compared to 7.4 seconds for the placebo group (p = 0.08). Altamira plans to submit an IND application to the FDA for AM-125 and aims to partner or divest this asset as it shifts focus towards RNA delivery technology.
Altamira Therapeutics (Nasdaq: CYTO) leverages its peptide-based SemaPhore™ nanoparticle technology to provide an innovative alternative to lipid nanoparticles (LNPs) in mRNA delivery.
SemaPhore offers enhanced stability, non-immunogenic properties, and efficient endosomal release, enabling its use for extrahepatic targets.
With over 840 mRNA programs in development, the limitations of LNPs highlight the significance of SemaPhore's capabilities, including effective cellular uptake and superior delivery rates.
Altamira is focused on serious unmet medical needs, currently advancing two flagship siRNA programs for KRAS-driven cancer and rheumatoid arthritis.
Altamira Therapeutics (Nasdaq:CYTO) announced positive results from a meta-analysis highlighting the effectiveness of betahistine in treating posterior canal benign paroxysmal positional vertigo (BPPV). The study included 860 patients and showed a statistically significant reduction in dizziness handicap when betahistine was added to the Epley maneuver (p = 0.001). The company plans to file an IND application for AM-125, an intranasal formulation of betahistine, with the FDA in May 2023, alongside the protocol for a Phase 2 clinical trial targeting BPPV. This development aligns with Altamira's strategic pivot towards its RNA delivery technology platforms, with intentions to partner or divest AM-125 as a legacy asset.
Altamira Therapeutics (Nasdaq:CYTO) announced research results indicating that ZBTB46 mRNA nanoparticles, delivered via the SemaPhore™ platform, effectively restricted tumor growth in mice. This study conducted by Washington University highlighted that ZBTB46 expression created an immunostimulatory tumor microenvironment, especially when combined with anti-PD1 immune checkpoint inhibitors. The treatment led to complete remission in several cases, suggesting ZBTB46 as a promising target for cancer therapy. These results may enhance the potential of Altamira's RNA-based therapeutics in oncology and signify a strategic advance in their development pipeline.
Altamira Therapeutics (Nasdaq:CYTO) announced promising results from an animal study demonstrating the efficacy of its SemaPhore delivery platform for mRNA therapeutics in treating osteoarthritis. The study, conducted by leading research groups, showed effective reduction of osteoarthritis progression in mice treated with DNMT3B mRNA nanoparticles. The findings, to be presented at the OARSI World Congress, highlight significant reductions in cartilage degeneration and pain sensitivity in treated subjects. This advancement represents a notable step towards potential disease-modifying therapies for osteoarthritis, which currently affects over 32.5 million US adults.
Altamira Therapeutics (NASDAQ:CYTO) announced significant findings from a clinical study on its nasal spray Bentrio. The study demonstrated that Bentrio retained effectiveness in nasal passages for up to 210 minutes, significantly longer than the 60 minutes for saline spray. This prolonged duration indicates enhanced protection against airborne allergens. Key insights include Bentrio's formulation allowing extended nasal residence without hindering mucociliary clearance. The research was published in the journal Drug Development and Industrial Pharmacy. The study was conducted with eight healthy volunteers and emphasizes Bentrio's advantages over traditional saline solutions.